How Tenvie Therapeutics is testing whether neuroinflammation can become the next obesity treatment frontier
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.